To stimulate or withdraw? A cost-utility analysis of recombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 4, 2010, Pages 1672-1680

  Wang, Tracy S ^a   Cheung, Kevin ^b   Mehta, Pritesh ^c   Roman, Sanziana A ^c   Walker, Hugh D ^d   Sosa, Julie Ann ^c  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROXINE; RECOMBINANT PROTEIN; THYROTROPIN;

ARTICLE; CANCER SURGERY; COMPARATIVE STUDY; COST UTILITY ANALYSIS; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; REIMBURSEMENT; SENSITIVITY ANALYSIS; SHORT FORM 36; THYROID CANCER; THYROIDECTOMY; TREATMENT WITHDRAWAL; TUMOR ABLATION; UNITED STATES; ADULT; COST; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DECISION TREE; ECONOMICS; QUALITY ADJUSTED LIFE YEAR; THYROID TUMOR; TUMOR RECURRENCE;

ADULT; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DECISION SUPPORT TECHNIQUES; DECISION TREES; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MARKOV CHAINS; NEOPLASM RECURRENCE, LOCAL; QUALITY-ADJUSTED LIFE YEARS; RECOMBINANT PROTEINS; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN; THYROXINE; UNITED STATES;

EID: 77951632915     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-1803     Document Type: Article

References (44)

1. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM; the American Thyroid Association Guidelines Taskforce 2006 Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16:109-142
2. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W; European Thyroid Cancer Taskforce 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787-803
3. Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, Tennvall J, Bombardieri E 2008 Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 35: 1941-1959
4. Kovatcheva RD, Hadjieva TD, Kirilov GG, Lozanov BS 2004 Recombinant human TSH in radioiodine treatment of differentiated thyroid cancer. Nucl Med Rev Cent East Eur 7:13-19 (Pubitemid 38745224)
5. Schlumberger M, Ricard M, De Pouvourville G, Pacini F 2007 How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer. Nat Clin Pract Endocrinol Metab 3:641-650
6. Luster M, Felbinger R, Dietlein M, Reiners C 2005 Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid 15:1147-1155
7. Davids T, Witterick IJ, Eski S, Walfish PG, Freeman JL 2006 Three-week thyroxine withdrawal: a thyroid-specific quality of life study. Laryngoscope 116:250-253
8. Duntas LH, Biondi B 2007 Short-term hypothyroidism after levothyroxine-withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences. Eur J Endocrinol 156:13-19
9. Nijhuis TF, van Weperen W, de Klerk JMH 1999 Costs associated with the withdrawal of thyroid hormone suppression therapy during the follow-up treatment of well-differentiated thyroid cancer. Tijdschr Nucl Geneeskd 21:98-100
10. Pacini F, Castagna MG 2008 Diagnostic and therapeutic use of recombinant TSH (rhTSH) in differentiated thyroid cancer. Best Pract Res Clin Endocrinol Metab 22:1009-1021
11. Haugen BR, Cooper DS, Emerson CH, Luster M, Maciel RM, Biscolla RP, Mazzaferri EL, Medeiros-Neto G, Reiners C, Robbins RJ, Robinson BG, Schlumberger M, Yamashita S, Pacini F 2008 Expanding indications for recombinant human TSH in thyroid cancer. Thyroid 18:687-694
12. Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR, Wondisford FE, Davies TF, DeGroot LJ, Daniels GH, Ross DS, Weintraub BD 1997 Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 337:888-896
13. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon 3rd HR, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC 1999 A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of remnant or cancer. J Clin Endocrinol Metab 84:3877-3885
14. Robbins RJ, Tuttle RM, Sharaf RN, Larson SM, Robbins HK, Ghossein RA, Smith A, Drucker WD 2001 Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 86:619-625
15. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, Lippi F, Taddei D, Grasso L, Pinchera A 2003 Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 88:3668-3673
16. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C 2006 Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 91:926-932
17. 131I is associated with lowered radiotoxicity. J Nucl Med 49:1776-1782
18. 131I effective half-life and dosimetry in thyroid cancer patients. J Nucl Med 49:1445-1450
19. Taïeb D, Sebag F, Cherenko M, Baumstarck-Barrau K, Fortanier C, Farman-Ara1 B, De Micco C, Vaillant J, Thomas S, Conte-Devolx B, Loundou A, Auquier P, Henry J, Mundler O 2009 Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation with recombinant human thyrotropin: a randomized controlled study. Clin Endocrinol (Oxf) 71: 115-123
20. Mernagh P, Campbell S, Dietlein M, Luster M, Mazzaferri E, Weston AR 2006 Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective. Eur J Endocrinol 155:405-414
21. Mernagh P, Suebwongpat A, Silverberg J, Weston A 8 Oct 2009 Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer: the Canadian perspective. Value Health doi: 10.1111/j.1524-4733.2009.00650.x
22. Tuttle RM, Brokhin M, Omry G, Martorella AJ, Larson SM, Grewal RK, Fleisher M, Robbins RJ 2008 Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med 49:764-770
23. Lefevre J, Tresallet C, Leenhardt L, Jublanc C, Chigot JP, Menegaux F 2007 Reoperative surgery for thyroid disease. Lang Arch Surg 392;685-691
24. Clayman GL, Shellenberger TD, Ginsberg LE, Edeiken BS, El-Naggar AK, Sellin RV, Waguespack SG, Roberts DB, Mishra A, Sherman SI 2009 Approach and safety of comprehensive central compartment dissection in patients with recurrent papillary thyroid carcinoma. Head Neck 31:1152-1163
25. Medical Services Advisory Committee 2002 Recombinant human thyroid stimulating hormone (rhTSH)-diagnostic agent in use for well-differentiated thyroid cancer. Canberra: Commonwealth of Australia
26. Kebebew E, Duh QY, Clark OH 2000 Total thyroidectomy or thyroid lobectomy in patients with low-risk differentiated thyroid cancer: surgical decision-analysis of a controversy using a mathematical model. World J Surg 24:1295-1302
27. Medicare reimbursement schedule. Available at: http://www.cms.hhs.gov/ home/rsds.asp
28. Bureau of Labor Statistics 2009 Labor force statistics from the current population survey (cited June 1, 2009). Available at: http://www.bls.gov/cps/ tables.htm
29. Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, Pacini F, Reiners C, Sánchez Franco F, Toft A, Wiersinga WM 2004 Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 150:105-112 (Pubitemid 38312801)
30. Borget I, Corone C, Nocaudie M, Allyn M, Iacobelli S, Schlumberger M, De Pouvourville G 2007 Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal. Eur J Endocrinol 156:531-538
31. Brown ML, Riley GF, Schussler N, Etzioni R 2002 Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care 40(Suppl 8): IV-104-117
32. Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos RT, Sherman SI, Haugen B, Corone C, Molinaro E, Grasso L, Leboulleux S, Rachinsky I, Luster M, Lassmann M, Busaidy NL, Wahl RL, Pacini F, Cho SY, Magner J, Pinchera A, Ladenson PW 2009 Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab 94:4171-4179
33. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, Dondon MG, Abbas MT, Langlois C, Schlumberger M 2003 Second primary malignancies in thyroid cancer patients. Br J Can 89:1638-1644
34. Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J, Grosclaude P, Hédelin G, Matsuda T, Møller H, Möller T, Verdecchia A, Capocaccia R, Gatta G, Micheli A, Santaquilani M, Roazzi P, Lisi D 2003 EUROCARE-3: survival of cancer patients diagnosed 1990-1994 - results and commentary. Ann Oncol 14: v61-v118
35. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ 2008 Cancer statistics, 2008. CA Cancer J Clin 58:71-96
36. Grubbs EG, Rich TA, Li G, Sturgis EM, Younes MN, Myers JN, Edeiken-Monroe B, Fornage BD, Monroe DP, Staerkel GA, Williams MD, Waguespack SG, Hu MI, Cote G, Gagel RF, Cohen J, Weber RS, Anaya DA, Holsinger FC, Perrier ND, Clayman GL, Evans DB 2008 Recent advances in thyroid cancer. Curr Probl Surg 45:156-250
37. Barbaro D, Boni G, Meucci G, Simi U, Lapi P, Orsini P, Pasquini C, Piazza F, Caciagli M, Mariani G 2003 Radioiodine treatment with 30mCiafter recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 88:4110-4115
38. Pilli T, Brianzoni E, Capoccetti F, Castagna MG, Fattori S, Poggiu A, Rossi G, Ferretti F, Guarino E, Burroni L, Vattimo A, Cipri C, Pacini F 2007 A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 92:3542-3546
39. McLeod RS, Geerts WH, Sniderman KW, Greenwood C, Gregoire RC, Taylor BM, Silverman RE, Atkinson KG, Burnstein M, Marshall JC, Burol CJ, Anderson DR, Ross T, Wilson SR, Barton P, Canadian Colorectal Surgery DVT Prophylaxis Trial 2001 Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery. Ann Surg 233:438-444
40. Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, Cooper DS, Schuff KG, Braverman LE, Skarulis MC, Davies TF, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Weintraub BD, Ridgway EC, Ladenson PW 2006 A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab 91:878-884
41. Hänscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C 2006 Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 47:648-654
42. Borget I, Remy H, Chevalier J, Ricard M, Allyn M, Schlumberger M, De Pouvourville G 2008 Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and Thyrogen. Eur J Nucl Med Mol Imaging 35:1457-1463
43. Watt T, Bjorner JB, Groenvold M, Rasmussen AK, Bonnema SJ, Hegedüs L, Feldt-Rasmussen U 2009 Establishing construct validity for the thyroid-specific patient reported outcome measure (ThyPRO): an initial examination. Qual Life Res 18:483-496
44. Gning I, Trask PC, Mendoza TR, Harle MT, Gutierrez KA, Kitaka SA, Sherman SI, Cleeland CS 2009 Development and initial validation of the thyroid cancer module of the M. D. Anderson symptom inventory. Oncology 76:59-68